Novo Nordisk A/S, of Bagsvaerd, Denmark, reported positive results from pathfinder2, the first phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients. Read More
Cellceutix Corp., of Beverly, Mass., said the seventh cohort is under way in the phase I trial of anticancer drug candidate, Kevetrin, dosing 165 mg/m2 of Kevetrin compared to 110 mg/m2 in the prior cohort. Read More
Bioalliance Pharma SA, of Paris, said it executed a license agreement with Innocutis Holding LLC, of Charleston, S.C., to commercialize Sitavig (acyclovir Lauriad) for the treatment of recurrent labial herpes in North America. Under the terms, Bioalliance is eligible to receive a total of $5 million up front and milestone payments. Read More
C3 Jian Inc., of Los Angeles, said it closed a series D financing for total proceeds of $60.5 million that will be used to support continued clinical development of their lead product, C16G2, a proprietary peptide-based antimicrobial drug specifically targeting Streptococcus mutans. Read More
Still enrolling a pivotal trial of its own Factor Xa inhibitor betrixaban, Portola Pharmaceuticals Inc. launched a new phase III study, this one testing andexanet alfa, designed to reverse the action of the anticoagulant class. Read More
Whether the needs of the many outweigh the needs of the few is the debate swirling around the FDA’s proposed rule that would allow generic drugmakers to change their labeling independent of the brand drug. Read More
Shares in Medigene AG edged up 8 percent Thursday on news of a licensing deal for its small-molecule CD80 (B7-1) inhibitor Rhudex with Dr. Falk Pharma GmbH. Read More
The bulls marched on as Alder Biopharmaceuticals Inc. joined the growing queue of biotechs seeking to prevail on the public markets. The Bothell, Wash.-based company filed a registration statement with the SEC seeking to raise up to $115 million in its initial public offering (IPO) to fund its ongoing clinical program for lead compound ALD403, a monoclonal antibody targeting calcitonin gene-related peptide, or CGRP, to prevent migraine headache. Read More
